Back
Standard BioTools Quote, Financials, Valuation and Earnings
Invest. Do Good. Get Rewarded. Just $0.25/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
41
LAB
Standard BioTools
Last Price:
1.65
Seasonality Move:
14.46%
7 Day Trial
ALL ACCESS PASS
$
7
Access The Stock Grader Trading Tool From "The King Of Quants"
More details here...Standard BioTools Price Quote
$1.65
+0.03 (+1.85%)
(Updated: November 22, 2024 at 12:20 PM ET)
Standard BioTools Key Stats
Sell
41
Standard BioTools (LAB)
is a Sell
Day range:
$1.56 - $1.67
52-week range:
$1.21 - $3.04
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.90
P/B ratio:
1.23%
Volume:
2M
Avg. volume:
2.2M
1-year change:
-29.57%
Market cap:
$603.1M
Revenue:
$106.3M
EPS:
$-0.71
How Much Does Standard BioTools Make?
-
How Much Are Standard BioTools's Sales Annually?
LAB Revenues are $106.3M -
How Much Profit Does Standard BioTools's Make A Year?
LAB net income is -$74.7M
Is Standard BioTools Growing As A Company?
-
What Is Standard BioTools's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.77% -
What Is Standard BioTools's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Standard BioTools Stock Price Performance
-
Did Standard BioTools Stock Go Up Last Month?
Standard BioTools share price went down by -13.83% last month -
Did LAB's Share Price Rise Over The Last Year?
LAB share price fell by -29.57% over the past 1 year
What Is Standard BioTools 52-Week High & Low?
-
What Is Standard BioTools’s 52-Week High Share Price?
Standard BioTools has traded as high as $3.04 over the past 52 weeks -
What Is Standard BioTools’s 52-Week Low Share Price?
Standard BioTools has traded as low as $1.21 over the past 52 weeks
Standard BioTools Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Standard BioTools?
-
How Much Debt Does Standard BioTools Have?
Total long term debt quarterly is $55.2M -
How Much Cash Does Standard BioTools Have?
Cash and short term investments quarterly total is $366.3M -
What Is Standard BioTools’s Book Value Per Share?
Book value per share is 1.31
Is Standard BioTools Cash Flow Positive?
-
What Is LAB Cash Flow From Operations?
Cash flow from operations (TTM) is -$143.5M -
What Is Standard BioTools’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$49.1M -
What Is Standard BioTools’s Cash Flow From Investing?
Cash flow from investing (TTM) is $324.3M
Standard BioTools Return On Invested Capital
-
Is Management Doing A Good Job?
LAB return on invested capital is -39.17% -
What Is Standard BioTools Return On Assets?
ROA measures how assets are converting to revenues and is -22.01% -
What Is LAB Return On Equity?
ROE is a measure of profitability and is -48.03%
Standard BioTools Earnings Date & Stock Price
-
What Is Standard BioTools's Stock Price Today?
A single share of LAB can be purchased today for 1.62 -
What Is Standard BioTools’s Stock Symbol?
Standard BioTools trades on the nasdaq under the ticker symbol: LAB -
When Is Standard BioTools’s Next Earnings Date?
The next quarterly earnings date for Standard BioTools is scheduled on February 28, 2025 -
When Is LAB's next ex-dividend date?
Standard BioTools's next ex-dividend date is November 22, 2024 -
How To Buy Standard BioTools Stock?
You can buy Standard BioTools shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Standard BioTools Competitors
-
Who Are Standard BioTools's Competitors?
Below is a list of companies who compete with Standard BioTools or are related in some way:
Standard BioTools Dividend Yield
-
What Is LAB Dividend Yield?
Standard BioTools’s dividend yield currently is 0% -
What Is Standard BioTools’s Payout Ratio?
Standard BioTools’s payout ratio is 0% -
When Did Standard BioTools Last Pay A Dividend?
The latest dividend pay date is November 22, 2024 -
What Is Standard BioTools’s Dividend Per Share?
Standard BioTools pays a dividend of $0.00 per share
Standard BioTools Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 53.87% |
| Revenue: | 77.27% | 9.68% |
Analyst Recommendations
| Buy Recommendations: | 3 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 3.08 |
| Upside from Last Price: | 90.33% |